Quoin Pharmaceuticals Ltd
QNRX7.140USD
-0.680-8.70%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
146.98MMarket Cap
LossP/E TTM
More Details of Quoin Pharmaceuticals Ltd Company
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Quoin Pharmaceuticals Ltd Info
Ticker SymbolQNRX
Company nameQuoin Pharmaceuticals Ltd
IPO dateNov 01, 1989
CEOMyers (Michael)
Number of employees3
Security typeDepository Receipt
Fiscal year-endNov 01
Address23 Hata'as Street
CityKFAR SABA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code44425
Phone97299741444
Websitehttps://quoinpharma.com/
Ticker SymbolQNRX
IPO dateNov 01, 1989
CEOMyers (Michael)
Company Executives of Quoin Pharmaceuticals Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
+440.00%
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
+440.00%
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Feb 4
Updated: Wed, Feb 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ikarian Capital LLC
13.09%
Stonepine Capital Management, LLC
5.78%
abrdn Inc.
4.64%
Resolute Capital Asset Partners LLC
3.09%
AIGH Capital Management, LLC.
2.23%
Other
71.17%
Shareholders
Shareholders
Proportion
Ikarian Capital LLC
13.09%
Stonepine Capital Management, LLC
5.78%
abrdn Inc.
4.64%
Resolute Capital Asset Partners LLC
3.09%
AIGH Capital Management, LLC.
2.23%
Other
71.17%
Shareholder Types
Shareholders
Proportion
Hedge Fund
13.09%
Investment Advisor/Hedge Fund
10.55%
Individual Investor
3.54%
Investment Advisor
3.17%
Private Equity
2.23%
Venture Capital
0.85%
Research Firm
0.02%
Other
66.55%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
31
434.83K
30.27%
+393.44K
2025Q3
28
2.54K
0.30%
-52.73K
2025Q2
34
51.05K
8.68%
-35.06K
2025Q1
35
78.22K
9.34%
-7.90K
2024Q4
33
2.93M
35.77%
+2.56M
2024Q3
29
288.95K
5.54%
-93.09K
2024Q2
30
301.96K
12.37%
-13.30K
2024Q1
28
276.13K
11.96%
+132.88K
2023Q4
28
104.03K
10.54%
-33.36K
2023Q3
27
83.72K
8.48%
+6.49K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ikarian Capital LLC
211.54K
25.21%
+211.54K
--
Nov 30, 2025
Stonepine Capital Management, LLC
58.73K
7%
+58.73K
--
Dec 10, 2025
Resolute Capital Asset Partners LLC
50.00K
5.96%
+50.00K
--
Oct 10, 2025
Myers (Michael)
17.22K
2.05%
--
--
Jul 16, 2025
Carter (Denise P)
17.22K
2.05%
-1.00
-0.01%
Jul 16, 2025
Langer (Dennis H)
15.15K
1.81%
+15.15K
+1515200.00%
Oct 14, 2025
Dunn (Gordon)
4.32K
0.51%
--
--
Jul 16, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 26, 2025
Merger
35→1
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Date
Ex-dividend Date
Type
Ratio
Mar 26, 2025
Merger
35→1
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
View more
